Range Impact Inc (RNGE)

[236T568]

Update - SEC INVESTIGATION - Vitality Biopharma Inc. (VBIO) states that it is being investigated by the SEC for false and misleading statements in their August 2016 S-1 registration statement filed with the SEC

Document Subpoenas Issued

CEO receives subpoena to provide testimony, which is estimated to be by the end of December 2017




https://www.sec.gov/Archives/edgar/data/1438943/000149315217008899/form10-q.htm

7. COMMITMENTS

On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. We received subpoenas to produce documents dated December 14, 2016, and January 23, 2017, and a further subpoena for testimony and any supplemental production of documents dated June 5, 2017. The document requests were primarily in connection with this matter. We have complied with all document requests and the Company’s CEO will provide testimony when the SEC schedules such testimony, which we believe will be sometime before the end of December 2017.

As of June 30, 2017, we had accrued approximately $44,000 in legal fees related to the SEC examination.